Intellectus Partners LLC Cuts Position in Intellia Therapeutics, Inc. $NTLA

Intellectus Partners LLC lessened its position in shares of Intellia Therapeutics, Inc. (NASDAQ:NTLA) by 41.2% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 51,125 shares of the company’s stock after selling 35,850 shares during the quarter. Intellectus Partners LLC’s holdings in Intellia Therapeutics were worth $460,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Contrarius Group Holdings Ltd boosted its holdings in shares of Intellia Therapeutics by 279.4% in the 3rd quarter. Contrarius Group Holdings Ltd now owns 5,889,936 shares of the company’s stock worth $101,719,000 after purchasing an additional 4,337,428 shares during the period. Vanguard Group Inc. boosted its holdings in shares of Intellia Therapeutics by 17.8% in the 4th quarter. Vanguard Group Inc. now owns 13,010,001 shares of the company’s stock worth $116,960,000 after purchasing an additional 1,965,181 shares during the period. Jupiter Asset Management Ltd. purchased a new position in shares of Intellia Therapeutics in the 3rd quarter worth approximately $23,519,000. Farallon Capital Management LLC purchased a new position in shares of Intellia Therapeutics in the 3rd quarter worth approximately $10,486,000. Finally, BNP Paribas Financial Markets boosted its holdings in shares of Intellia Therapeutics by 1,076.6% in the 4th quarter. BNP Paribas Financial Markets now owns 591,277 shares of the company’s stock worth $5,316,000 after purchasing an additional 541,026 shares during the period. Hedge funds and other institutional investors own 88.77% of the company’s stock.

Intellia Therapeutics Stock Performance

Shares of NTLA stock opened at $14.75 on Friday. Intellia Therapeutics, Inc. has a 52-week low of $7.31 and a 52-week high of $28.25. The firm has a market capitalization of $2.06 billion, a P/E ratio of -4.17 and a beta of 1.92. The stock has a 50 day moving average price of $13.60 and a 200 day moving average price of $12.13.

Intellia Therapeutics (NASDAQ:NTLA) last issued its quarterly earnings results on Monday, May 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.11. Intellia Therapeutics had a negative return on equity of 57.47% and a negative net margin of 597.04%.The firm had revenue of $15.05 million during the quarter, compared to analyst estimates of $13.81 million. During the same period last year, the company earned ($1.10) EPS. As a group, sell-side analysts forecast that Intellia Therapeutics, Inc. will post -3.29 EPS for the current year.

Wall Street Analysts Forecast Growth

NTLA has been the subject of a number of recent research reports. reiterated a “buy” rating on shares of Intellia Therapeutics in a report on Tuesday, March 3rd. Wells Fargo & Company lifted their target price on Intellia Therapeutics from $12.00 to $15.00 and gave the stock an “equal weight” rating in a report on Tuesday, March 3rd. Wedbush reiterated a “neutral” rating and issued a $12.00 target price on shares of Intellia Therapeutics in a report on Tuesday, May 12th. Canaccord Genuity Group decreased their price target on Intellia Therapeutics from $58.00 to $49.00 and set a “buy” rating for the company in a research note on Tuesday, May 12th. Finally, Leerink Partners set a $35.00 price target on Intellia Therapeutics in a research note on Monday, April 27th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, ten have given a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $20.25.

Intellia Therapeutics Profile

Intellia Therapeutics, Inc (NASDAQ: NTLA) is a clinical‐stage biotechnology company focused on developing potentially curative genome editing therapies using the CRISPR/Cas9 platform. The company’s research spans both in vivo and ex vivo applications of CRISPR/Cas9, aiming to correct or disable disease‐causing genes with a single administration. Intellia’s lead in vivo program targets transthyretin amyloidosis (ATTR) by delivering CRISPR/Cas9 machinery directly to the liver, while additional preclinical efforts pursue treatments for hemophilia A, hereditary angioedema and other genetic disorders.

Beyond its in vivo pipeline, Intellia collaborates with strategic partners to extend the impact of its genome editing approach.